may have a role in the results of the article by Brance et al. [1] . We hope that considering this condition would add to the value of the well-written article of Brance et al. [1] vitamin D levels and bone mass in RA. To the Editors,
To the Editors,
With great interest, we read the recent article by Brance et al. [1] vitamin D levels and bone mass in rheumatoid arthritis (RA). The authors discussed very clearly the relation between vitamin D and disease activity. They concluded that patients with RA had lower 25(OH)D levels than the control group and that low levels of 25(OH)D were related to moderate-high disease activity. Also, they found that bone mass was lower in the femoral neck of postmenopausal patients with RA.
The authors suggested exclusion criteria as follows: had a history of neoplasia or had taken drugs that affect bone metabolism, including bisphosphonates, calcium and vitamin D supplements in the last 12 months or were receiving oral glucocorticoids (>10 mg/day prednisone or equivalent) in the last 3 months. In addition to their fluent exclusion criteria, we aimed to emphasize that possible thyroid dysfunctions may affect bone mineral mass [2, 3] . The overall prevalence of hyperthyroidism, which is approximately 1.3 %, increases to 4-5 % in older women [4] . Because of the high prevalence among elderly population, we believe that the effect of thyroid hormones on bone metabolism
